Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25,…
WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with Datavant, the…
Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III…
–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular…
– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical…
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its…
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube…
Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.–(BUSINESS WIRE)–$A #BringGreatScienceToLife—Agilent Technologies Inc.…
Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabetes…
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior…